SCHEMBL6484953

SCHEMBL6484953

CN(C)C(=O)c1c[nH]c2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.66
GPR84 Q9NQS5 1/20 0.65
ALDH1A1 P00352 2/20 0.61
ATM Q13315 1/20 0.61
NR4A2 P43354 2/20 0.60
CREBBP Q92793 1/20 0.60
KMT2A Q03164 1/20 0.57
MAPK1 P28482 1/20 0.56
CTNNB1 P35222 2/20 0.55
WNT3A P56704 2/20 0.55
TP53 P04637 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
ADAM17 P78536 1/20 0.53
LMNA P02545 1/20 0.53
HAT1 O14929 1/20 0.52
EP300 Q09472 1/20 0.52
NPC1 O15118 1/20 0.51
CDK4 P11802 1/20 0.51
CCND1 P24385 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29557695 1.00 PBRM1 (0.66) PBRM1GPR84ALDH1A1ATMNR4A2
Hydrochloric Acid SCHEMBL29013059 0.98 PBRM1 (0.64) PBRM1GPR84ALDH1A1ATMNR4A2
SCHEMBL7457775 0.86 ALDH1A1 (0.62) PBRM1GPR84ALDH1A1ATMNR4A2
SCHEMBL5316085 0.83 NR4A2 (0.62) PBRM1GPR84ALDH1A1ATMNR4A2
SCHEMBL13763424 0.83 PBRM1 (0.58) PBRM1GPR84ALDH1A1ATMNR4A2
SCHEMBL13757483 0.83 PBRM1 (0.58) PBRM1GPR84ALDH1A1ATMNR4A2
SCHEMBL29414387 0.83 PBRM1 (0.62) PBRM1GPR84ALDH1A1ATMNR4A2
SCHEMBL4215371 0.83 PBRM1 (0.62) PBRM1GPR84ALDH1A1ATMNR4A2
SCHEMBL27275913 0.81 CDK4 (0.58) PBRM1GPR84ALDH1A1ATMNR4A2
SCHEMBL7879664 0.81 ALDH1A1 (0.59) PBRM1GPR84ALDH1A1ATMNR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612424-B2 HPK1 inhibitors and uses thereof REGOR PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-07-04 US disclosed
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2022-12-08 US disclosed
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2022-12-08 US disclosed
CN-114555585-A HPK1 inhibitors and uses thereof 上海齐鲁锐格医药研发有限公司 2022-05-27 CN disclosed
EP-3994133-A1 HPK1 INHIBITORS AND USES THEREOF Qilu Regor Therapeutics Inc. (CN) 2022-05-11 EP disclosed
WO-2021000935-A1 HPK1 INHIBITORS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2021-01-07 WO disclosed
WO-2021000935-A1 HPK1 INHIBITORS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2021-01-07 WO disclosed
US-8735414-B2 Indole derivatives and methods for antiviral treatment PTC THERAPEUTICS, INC. (US) 2014-05-27 US disclosed
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT PTC THERAPEUTICS, INC. (US) 2012-07-19 US disclosed
US-6852726-B2 Substituted indoles as alpha-1 agonists SYNTEX LLC (US) 2005-02-08 US disclosed
EP-1181296-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2002-02-27 EP disclosed
WO-2000075145-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2000-12-14 WO disclosed
US-5219859-A Chloesterol acyltransferase inhibitors; antilipemic agents; antidiabetic agents; atherosclerosis LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) 1993-06-15 US disclosed
EP-0506532-A1 Indole derivatives, process for their preparation and medicaments containing them LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) 1992-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612424-B2 HPK1 inhibitors and uses thereof NEK11, NEK1, CSNK1A1 PBRM1 1490/4885GPR84 1636/4885ALDH1A1 3619/4885
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF HIPK1, SIK1, PGK1 PBRM1 1514/4885GPR84 3686/4885ALDH1A1 3740/4885
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT IDO1, IRF3, MAVS PBRM1 4549/4885GPR84 1891/4885ALDH1A1 2672/4885
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, DPYD PBRM1 164/4885GPR84 3994/4885ALDH1A1 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.